

Resource Summary Report

Generated by [NIF](#) on Aug 20, 2026

eIF4E (C46H6) Rabbit mAb

RRID:AB_2097675

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2067, RRID:AB_2097675

Antibody Information

URL: http://antibodyregistry.org/AB_2097675

Proper Citation: Cell Signaling Technology Cat# 2067, RRID:AB_2097675

Target Antigen: EIF4E

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P. Consolidation on 10/2018: AB_10343611, AB_10828612, AB_2097675.

Antibody Name: eIF4E (C46H6) Rabbit mAb

Description: This monoclonal targets EIF4E

Target Organism: rat, mouse, human

Antibody ID: AB_2097675

Vendor: Cell Signaling Technology

Catalog Number: 2067

Record Creation Time: 20250820T012310+0000

Record Last Update: 20250820T104729+0000

Ratings and Alerts

No rating or validation information has been found for eIF4E (C46H6) Rabbit mAb.

No alerts have been found for eIF4E (C46H6) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Powers J, et al. (2026) eIF4G2-dependent translation restrains pancreatic cancer progression. bioRxiv : the preprint server for biology.

Peng H, et al. (2026) Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis. Nature communications, 17(1).

Kadowaki H, et al. (2026) Sec61? maintains cytoplasmic proteostasis via ARIH1-mediated translational repression upon ER stress. EMBO reports, 27(4), 1057.

Powers J, et al. (2026) eIF4G2-Dependent Translation Restrains Pancreatic Cancer Progression. Cancer research.

MacMillan AC, et al. (2025) PRPS activity tunes redox homeostasis in Myc-driven lymphoma. Redox biology, 84, 103649.

Liu B, et al. (2025) The hexosamine biosynthetic pathway drives tumor immune evasion via translational control of PD-L1 at the elongation level. Cell reports, 44(9), 116249.

Li SB, et al. (2025) OASL enhances mRNA translation and reprograms lipid metabolism to promote cancer progression. Cell reports, 44(7), 115901.

Fowler CE, et al. (2025) The PRMT5-splicing axis is a critical oncogenic vulnerability that regulates detained intron splicing. iScience, 28(7), 112965.

Toyokuni E, et al. (2025) Combination therapy of avutemetinib and MRTX1133 synergistically suppresses cell growth by inducing apoptosis in KRASG12D-mutated pancreatic cancer. Molecular cancer therapeutics.

Belcher DJ, et al. (2024) Anabolic deficits and divergent unfolded protein response underlie skeletal and cardiac muscle growth impairments in the Yoshida hepatoma tumor model of cancer cachexia. Physiological reports, 12(18), e70044.

Cao Y, et al. (2023) Enhanced bypass of PD-L1 translation reduces the therapeutic response to mTOR kinase inhibitors. Cell reports, 42(7), 112764.

Surani AA, et al. (2022) Implications of differential transcription start site selection on chronic myeloid leukemia and prostate cancer cell protein expression. iScience, 25(12), 105519.

Chen C, et al. (2022) Translational and post-translational control of human naïve versus primed pluripotency. iScience, 25(1), 103645.

Uchihara Y, et al. (2022) DNA damage promotes HLA class I presentation by stimulating a pioneer round of translation-associated antigen production. *Molecular cell*, 82(14), 2557.

Rong B, et al. (2020) Ribosome 18S m6A Methyltransferase METTL5 Promotes Translation Initiation and Breast Cancer Cell Growth. *Cell reports*, 33(12), 108544.

Lo LH, et al. (2020) The Protein Arginine Methyltransferase PRMT8 and Substrate G3BP1 Control Rac1-PAK1 Signaling and Actin Cytoskeleton for Dendritic Spine Maturation. *Cell reports*, 31(10), 107744.

Ryu I, et al. (2019) eIF4A3 Phosphorylation by CDKs Affects NMD during the Cell Cycle. *Cell reports*, 26(8), 2126.

Boulas K, et al. (2019) Identification of the m6Am Methyltransferase PCIF1 Reveals the Location and Functions of m6Am in the Transcriptome. *Molecular cell*, 75(3), 631.

Chan K, et al. (2019) eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. *Nature communications*, 10(1), 5151.

Ye Q, et al. (2019) Frenolicin B Targets Peroxiredoxin 1 and Glutaredoxin 3 to Trigger ROS/4E-BP1-Mediated Antitumor Effects. *Cell chemical biology*, 26(3), 366.